| scholarly article | Q13442814 |
| P50 | author | Heikki Joensuu | Q16299408 |
| Federico Piacentini | Q37839869 | ||
| Eva M Ciruelos | Q57085354 | ||
| Pirkko-Liisa Kellokumpu-Lehtinen | Q88043810 | ||
| Thomas Bachelot | Q89504757 | ||
| Petri Bono | Q114522981 | ||
| P2093 | author name string | Marc Espié | |
| Jungsil Ro | |||
| Sara Hurvitz | |||
| Joo Hyuk Sohn | |||
| Andreas Schneeweiss | |||
| Sung-Bae Kim | |||
| Javier Cortés | |||
| Emilie Le Rhun | |||
| Jean-Marc Nabholtz | |||
| Véronique Dieras | |||
| Flavien Roux | |||
| Jérôme Barriere | |||
| Julie Taguchi | |||
| Mahmoud Ould-Kaci | |||
| P2860 | cites work | A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab | Q24594725 |
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Q27853001 | ||
| Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. | Q30814798 | ||
| Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. | Q33425039 | ||
| Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease | Q34772704 | ||
| Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. | Q35608531 | ||
| CNS metastases in breast cancer | Q35874807 | ||
| Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer | Q35914677 | ||
| Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival | Q37132786 | ||
| Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases | Q37601140 | ||
| Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib | Q37651820 | ||
| The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. | Q40021112 | ||
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study | Q43522608 | ||
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 | ||
| Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study | Q46256397 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier | Q48341810 | ||
| Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases | Q49123747 | ||
| Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors | Q58849618 | ||
| Survival in patients with brain metastases from breast cancer: the importance of HER-2 status | Q80940181 | ||
| Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer | Q84529291 | ||
| P433 | issue | 16 | |
| P921 | main subject | brain | Q1073 |
| trastuzumab | Q412616 | ||
| brain metastasis | Q1620196 | ||
| P304 | page(s) | 1700-1710 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial | |
| P478 | volume | 16 |
| Q38681576 | Advances in systemic therapy for metastatic breast cancer: future perspectives. |
| Q39428826 | Breast cancer treatment-induced cardiotoxicity |
| Q27612411 | CIViC database |
| Q90291777 | Current state of clinical trials in breast cancer brain metastases |
| Q89544565 | Emerging findings into molecular mechanism of brain metastasis |
| Q97421387 | Evolving treatment strategies of brain metastases from breast cancer: current status and future direction |
| Q39034850 | HER2-positive breast cancer |
| Q64078065 | HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance |
| Q38728508 | Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer |
| Q89840115 | Landscape of combination therapy trials in breast cancer brain metastasis |
| Q54940766 | Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer. |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q92388559 | Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease |
| Q38861026 | Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations |
| Q50026716 | Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. |
| Q30846907 | Polypharmacology in Precision Oncology: Current Applications and Future Prospects |
| Q28072755 | Recent developments and translational aspects in targeted therapy for metastatic breast cancer |
| Q58108246 | Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials |
| Q92298870 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases |
| Q28068154 | Targeted Therapies for Brain Metastases from Breast Cancer |
| Q38715328 | Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors |
| Q39192200 | Targeted Treatment of Brain Metastases |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q98178296 | Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases |
| Q38887451 | Updates in the management of brain metastases. |
| Q90625429 | miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer |
Search more.